Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

Journal of Infectious Diseases

Volumn 196, Issue 4, 2007, Pages 591-598

  Bhattacharya, Sujit Kumar ^a,c   Sinha, Prabhat Kumar ^a   Sundar, Shyam ^d,e   Thakur, Chandreshar Prasad ^b   Jha, Tara Kant ^e   Pandey, Krishna ^a   Das, Vidyanand Rabi ^a   Kumar, Naveen ^a   Lal, Chandrasekhar ^a   Verma, Neena ^a   Singh, Vijay Pratap ^a   Ranjan, Alok ^a   Verma, Rakesh Bihari ^a   Anders, Gerlind ^g   Sindermann, Herbert ^g   Ganguly, Nirmal Kumar ^f  

^a RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

^b Balaji Utthan Sansthan   (India)

^c NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^d Kala azar Research Center   (India)

^e BANARAS HINDU UNIVERSITY   (India)

^f INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^g Zentaris GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE;

ABDOMINAL PAIN; ABDOMINAL SWELLING; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANASARCA; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; EPISTAXIS; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEMOPTYSIS; HOSPITAL PATIENT; HUMAN; INDIA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL BLEEDING; OUTPATIENT; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIPROTOZOAL AGENTS; ASPARTATE AMINOTRANSFERASES; CAPSULES; CHILD; CHILD, PRESCHOOL; CREATININE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; LIVER DISEASES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHOSPHORYLCHOLINE; TREATMENT OUTCOME;

EID: 34547628081     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/519690     Document Type: Article

References (18)

1. Singh SP, Reddy DCS, Rai M, Sundar S. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health 2006; 11:899-905.
2. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6:849-55; erratum, Trop Med Int Health 2002; 7:293.
3. Thakur CP. Sodium antimony gluconate, amphotericin, and myocardial damage. Lancet 1998; 351:1928-9.
4. Thakur CP, Narayan S. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 2004; 98:129-38.
5. Das VN, Ranjan A, Bimal S, et al. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Natl Med J India 2005; 18:131-3.
6. Thakur CP, Narayan S, Ranjan A. Epidemiological, clinical and pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 2004; 120:166-72.
7. Thakur CP, Dedet JP, Narayan S, Pratlong F. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India. Trans R Soc Trop Med Hyg 2001; 95:187-9.
8. Thakur CP, Sinha GP, Pandey AK, et al. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a firstline drug? An observational study of 80 cases. Ann Trop Med Parasitol 1998; 92:561-9.
9. Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis: determinant roles of renal failure and drug accumulation. A study of 126 patients. Diabetes Care 1995; 18:47-55.
10. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP. Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003; 37:800-4.
11. Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998; 352:1821-3.
12. Sundar S, Gupta LB, Makharia MK, et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999; 93:589-97.
13. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341:1795-800.
14. Sundar S, Makharia A, More DK, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000; 31:1110-3.
15. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine of Indian visceral leishmaniasis. New Engl J Med 2002; 347:1739-46.
16. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003; 22:434-8.
17. Bhattacharya SK, Jha TK, Sundar S, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004; 38:217-21.
18. Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100(Suppl 1):S17-20.